This Week in Practical Diabetology News

Similar A1c Effect for Intermittent vs Continually Restricted Diets

Researchers found that intermittent semi-fasting, with daily caloric intake kept below 600 kcal for 2 days per week, yielded a similar reduction in blood glucose when compared with a continual calorie-restricted diet. MedPage Today outlined these research findings. Click here for full story.

 

Nonheterosexual Youth May Be at Greater Diabetes Risk

Nonheterosexual adolescents may be at greater risk for developing type 2 diabetes compared with heterosexual teens, new research suggests. The study, reviewed by Medscape, was based on national data for 350,673 high school students aged 14–18 years who participated in the Youth Risk Behavior Survey (YRBS) during 2009–2015. Click here for full story.

 

Preventing dangerous episodes of low blood sugar with diabetes: Study provides next clue

A new study reveals that a novel biomarker might give us new answers necessary to creating a diagnostic tool for hypoglycemia-associated autonomic failure, or HAAF. Science Daily reports, no objective diagnostic tool currently exists for this condition which, if left untreated, can lead to ever-worsening and possibly life-threatening episodes of dangerously low blood sugar. Click here for full story.

 

Masked High Blood Pressure and Arterial Stiffness in Type 1 Diabetes

A recent ambulatory blood pressure (BP) monitoring analysis indicated that many individuals with type 1 diabetes also have masked hypertension, according to a study highlighted by Endocrinology Advisor. Research also suggested increased arterial stiffness and a greater risk for cardiovascular disease in these individuals. Click here for full story.

 

Diabetes drugs act as powerful curb for immune cells in controlling inflammation

According to a report on Science Daily, a common class of drugs used to treat diabetes has been found to exert a powerful check on macrophages by controlling the metabolic fuel they use to generate energy. Keeping macrophages from going overboard on the job may inhibit the onset of obesity and diabetes following tissue inflammation. Click here for full story.

 

Novel Therapies for Diabetes Mellitus in Pregnancy

The prevalence of diabetes during pregnancy has been increasing in recent years, according to a report on Practice Update. it is now more important than ever to understand the best treatment strategies for minimizing risk to both the mother and the unborn child. Click here for full story.

 

Poor Periconception Glycemic Control in Women With Type 1 Diabetes Increases Risk of Major Birth Defects

As stated by Practice Update, the authors of this population-based historical cohort study of 2458 singleton live-born infants of mothers with type 1 diabetes and 1,159,865 infants of mothers without diabetes sought to determine the association between maternal type 1 diabetes and the risk of major birth defects according to levels of HbA1c within 3 months before or after estimated conception. Click here for full story.

 

Week of July 16, 2018

 

Newer Diabetes Agents Show Promise for Renal Disease

Healio reports that large cardiovascular outcome trials for antidiabetes agents in two drug classes have yielded potentially promising data with respect to their secondary renal outcomes, offering new options for patients with diabetic kidney disease. Click here for full story.

 

Consider Patient Risk When Targeting BP in Diabetes

A debate continues over the optimal target for blood pressure management in type 2 diabetes with comorbid hypertension. Healio reports that some experts are pushing for a lower goal whenever possible, whereas others prefer a more individualized, patient-centered approach. Click here for full story.

 

TEDDY: More Small Clues to the Pathogenesis of Type 1 Diabetes

Medscape reports that more small clues to the development of islet autoimmunity prior to the onset of type 1 diabetes are emerging from The Environmental Determinants of Diabetes in the Young study. Click here for full story.

 

HbA1c Reduction Similar in Old, New Basal Insulin Analogues

Despite some differences in weight gain, most basal insulin analogs generally have similar glycemic control efficacy for patients with type 2 diabetes, according to a new study outlined by MedPage Today. Click here for full story.

 

‘Really Good’ New Guidelines for T2 Diabetes

Dr. Anne Peters talks about the new ASA/EASD treatment guidelines for managing patients with Type 2 diabetes for Medscape. Although guiding people is difficult, these guidelines actually begin to guide us in the treatment of our patients with type 2 diabetes. Click here for full story.

 

Experts Weigh Pros, Cons of Second-Line Diabetes Therapies

As reported by Healio, panelists at the Heart in Diabetes Clinical Education Conference presented their respective arguments for their choice of SGLT2 inhibitors vs. GLP-1 receptor agonists as second-line therapy after metformin. Click here for full story.

 

Week of July 9, 2018

 

Scientists Discover New Target to Treat Blood Vessel Damage in Diabetes

For those with diabetes, both the tightly woven endothelial cells that line our blood vessels and the powerhouses that drive those cells start to come apart as early steps in the destruction of our vasculature. As reported by News Medical, scientists now have evidence that these breakups occur as another relationship falls apart. Click here for full story.

 

Increased Incidence of Hospitalization for Heart Failure in People With Diabetes

According to a report from Practice Update, a study has found that heart failure is an under-recognized complication of Type 1 diabetes. The study found that people with diabetes had an increased incidence of hospitalization for heart failure. Click here for full story.

 

Verapamil May Improve Beta-Cell Function in Type 1 Diabetes

New research suggests that the old antihypertensive drug verapamil may help reduce insulin requirements and hypoglycemic episodes in adults with Type 1 diabetes. As reported by Medscape, verapamil appears to bolster the remaining endogenous beta-cell function, which has been shown to persist in people with type 1 diabetes longer than previously thought. Click here for full story.

 

Oestrogen Holds Promise for Diabetes Cure

Oestrogen can protect women who have been through menopause against Type 2 diabetes, according to a report outlined by Nature. Oestrogen does so by triggering the destruction of misfolded insulin proteins that accumulate during the early stages of the disease. Click here for full story.

 

Researchers Cure Type 2 Diabetes and Obesity in Mice Using Gene Therapy

A research team from the Universitat Autònoma de Barcelona, led by Professor Fatima Bosch has managed to cure obesity and type 2 diabetes in mice using gene therapy. As reported by MedicalXpress the gene therapy promoted healthy aging and prevented age-associated weight gain and insulin resistance in mice. Click here for full story.

 

Intensifying Treatment Does Not Negatively Affect Type 2 Diabetes

A new study outlined by Endocrinology Advisor found that intensifying treatment, including initiation of insulin, does not have an adverse impact on the well-being of community-dwelling patients with Type 2 diabetes. Previous research shows that the initiation of insulin did not affect health status or quality of life (QoL), although patients on chronic insulin therapy have demonstrated lower health status and diabetes-associated QoL vs those on other therapies. Click here for full story.

 

Very High HbA1c Falls Most With GLP-1 Agonist Plus Basal Insulin

Among patients with uncontrolled type 2 diabetes with very high HbA1c, two treatment regimens led to “dramatic improvements” in glycemic control at 6 months, but one strategy stood out, Medscape reports. A treatment regimen of basal insulin plus the glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide (Victoza, Novo Nordisk) was more effective at lowering HbA1c than a regimen of basal plus bolus insulin. Click here for full story.

 

Week of July 2, 2018

 

Carol and Mark A. Atkinson, PhD, Receive American Diabetes Association’s Humanitarian Award

Last week at the ADA’s 78th Scientific Sessions, Carol and Mark A. Atkinson, PhD, of Insulin for Life USA, received the American Diabetes Association’s Humanitarian Award. This one-time award honors their outstanding leadership and humanitarian efforts to support the diabetes community for the Diabetes Emergency Relief Coalition in 2017. Both Carol and Mark A. Atkinson will have upcoming contributions to the Practical Diabetology editorial line-up. Click here for full story.

 

RISE: Type 2 Diabetes More Aggressive in Adolescents; Early Treatment Unlikely to Slow Progression

According to new data from three RISE Studies, and outlined by Healio, early treatment with insulin and metformin does not substantially slow the progression of prediabetes or newly diagnosed Type 2 diabetes in adolescents, and they have a much more aggressive disease than adults with similar glycemic profiles. Click here for full story.

 

There’s Hope For a Vaccine to Prevent Type 1 Diabetes

In a new study, a small group of people with type 1 diabetes who were given a vaccine showed improvement in their blood sugar levels to nearly normal levels—and the changes lasted for five to eight years. As reported by Time Health, levels of their HbA1c dropped more than 10% three years after treatment and by more than 18% four years after treatment. Click here for full story.

 

FDA Clears New Point-of-Care HbA1c Assay

As reported by Healio, the FDA has cleared a rapid point-of-care test to diagnose diabetes and assess patient risk for developing diabetes. The Afinion HbA1c Dx assay is now cleared for use with the Afinion AS100 Analyzer, a multi-assay analyzer that provides near-patient testing of HbA1c and albumin to creatinine ratio at the point of care, according to a press release from Abbott. Click here for full story.

 

Novel Systems Could Expand ‘Hybrid Closed-Loop’ Field in Diabetes

Findings for three insulin delivery systems show promise for improving blood glucose levels in people with Type 1 diabetes. As reported by Medscape, the new data were discussed during a press briefing moderated by Irl B. Hirsch, MD, of the University of Washington, Seattle at the American Diabetes Association 2018 Scientific Sessions. Click here for full story.

 

Cost Issues Prevent a Quarter of Patients From Taking Insulin

A new study shows Cost issues related to insulin use prevent a full quarter of patients with diabetes taking insulin as prescribed. The study outlined by Medscape states that these cost issues are associated with poorer glycemic control. Click here for full story.

Pages: 1 2